959236-72-7 Usage
Uses
Used in Pharmaceutical Research:
2,4(1H,3H)-Quinazolinedione, 7-iodois used as a chemical building block or intermediate in the development of new drugs or other biologically active molecules. Its unique molecular structure and properties contribute to the design and synthesis of novel pharmaceutical compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 2,4(1H,3H)-Quinazolinedione, 7-iodoserves as a valuable intermediate for the synthesis of various complex organic molecules. Its reactivity and functional groups can be utilized in various chemical reactions, enabling the formation of diverse molecular structures with potential applications in various industries.
Used in Chemical Research:
2,4(1H,3H)-Quinazolinedione, 7-iodois employed in chemical research to explore its unique properties and reactivity, particularly due to its iodine substitution. This research can lead to a better understanding of the compound's behavior in various chemical reactions and its potential applications in the development of new materials or processes.
Used in Biological Research:
In biological research, 2,4(1H,3H)-Quinazolinedione, 7-iodomay be used to study its interactions with biological systems, such as proteins or enzymes. This can provide insights into its potential use in the development of new drugs or as a tool for understanding biological processes at the molecular level.
Check Digit Verification of cas no
The CAS Registry Mumber 959236-72-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,2,3 and 6 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 959236-72:
(8*9)+(7*5)+(6*9)+(5*2)+(4*3)+(3*6)+(2*7)+(1*2)=217
217 % 10 = 7
So 959236-72-7 is a valid CAS Registry Number.
959236-72-7Relevant academic research and scientific papers
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for β-catenin/t-cell transcriptional factor 4 pathway inhibition
Dehnhardt, Christoph M.,Venkatesan, Aranapakam M.,Chen, Zecheng,Ayral-Kaloustian, Semiramis,Dos Santos, Osvaldo Dos,Delos Santos, Efren,Curran, Kevin,Follettie, Max T.,Diesl, Veronica,Lucas, Judy,Geng, Yi,DeJoy, Susan Quinn,Petersen, Rosanne,Chaudhary, Inder,Brooijmans, Natasja,Mansour, Tarek S.,Arndt, Kim,Chen, Lei
experimental part, p. 897 - 910 (2010/07/05)
We are introducing a novel series of 2,4-diaminoquinazolines as β-catenin/Tcf4 inhibitors which were identified by ligand-based design. Here we elucidate the SAR of this series and explain how we were able to improve key molecular properties such as solubility and cLogP leading to compound 9. Analogue 9 exhibited better biological activity and improved physical and pharmacological properties relative to the HTS hit 49. Furthermore, 9 demonstrated good cell growth inhibition against several human colorectal cancer lines such as LoVo and HT29. In addition, treatment with compound 9 led to gene expression changes that overlapped significantly with the transcriptional profile resulting from the pathway inhibition by siRNA knockdown of β-catenin or Tcf4. Subsequently, 9 was tested for efficacy in a β-catenin/RKE-mouse xenograft, where it led to more then 50% decrease in tumor volume. 2009 American Chemical Society.
AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
-
, (2008/12/07)
The present invention relates to amino-substituted quinazoline derivatives as inhibitors of β-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
